среда, 28 сентября 2016 г.

Why Cash Is King for Biotech Stocks

Why Cash Is King for Biotech Stocks


Successfully developing and commercializing next-generation medicine is incredibly difficult and expensive, and while some companies have the financial firepower to cross the finish line, many biotech stocks will run short on cash before then. In this clip from The Motley Fool's Industry Focus: Healthcare podcast,analyst Kristine Harjes and contributor Todd Campbell explain why cash and equivalents can be the most important thing that investors need to know before buying biotech stocks.



from Biotech News